NCT03907488 2026-04-13
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
National Cancer Institute (NCI)
The Affiliated People's Hospital of Ningbo University
Jiangsu HengRui Medicine Co., Ltd.
The Affiliated People's Hospital of Ningbo University
Xiamen Amoytop Biotech Co., Ltd.
ChineseAMS
Sun Yat-sen University